Adagene Past Earnings Performance
Past criteria checks 0/6
Adagene's earnings have been declining at an average annual rate of -2.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 17.9% per year.
Key information
-2.1%
Earnings growth rate
25.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 17.9% |
| Return on equity | -56.3% |
| Net Margin | -3,904.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Oct 10
The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically
Oct 05Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M
Aug 30Micro-cap Adagene surges after hours on $10M share buyback
Jun 29Revenue & Expenses Breakdown
How Adagene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -32 | 8 | 30 |
| 31 Mar 24 | 9 | -25 | 8 | 33 |
| 31 Dec 23 | 18 | -19 | 9 | 37 |
| 30 Sep 23 | 20 | -28 | 9 | 47 |
| 30 Jun 23 | 23 | -36 | 10 | 57 |
| 31 Mar 23 | 16 | -58 | 11 | 69 |
| 31 Dec 22 | 9 | -80 | 12 | 81 |
| 30 Sep 22 | 11 | -82 | 13 | 82 |
| 30 Jun 22 | 13 | -84 | 14 | 81 |
| 31 Mar 22 | 11 | -78 | 14 | 75 |
| 31 Dec 21 | 10 | -73 | 14 | 68 |
| 30 Sep 21 | 6 | -68 | 14 | 60 |
| 30 Jun 21 | 2 | -62 | 13 | 50 |
| 31 Mar 21 | 1 | -52 | 12 | 42 |
| 31 Dec 20 | 1 | -43 | 10 | 34 |
| 30 Sep 20 | 1 | -34 | 9 | 28 |
| 30 Jun 20 | 1 | -28 | 7 | 24 |
| 31 Mar 20 | 1 | -22 | 5 | 20 |
| 31 Dec 19 | 0 | -17 | 4 | 16 |
| 31 Dec 18 | 2 | -14 | 3 | 16 |
Quality Earnings: ADAG is currently unprofitable.
Growing Profit Margin: ADAG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ADAG is unprofitable, and losses have increased over the past 5 years at a rate of 2.1% per year.
Accelerating Growth: Unable to compare ADAG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADAG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ADAG has a negative Return on Equity (-56.28%), as it is currently unprofitable.